Logo image of SRRK

SCHOLAR ROCK HOLDING CORP (SRRK) Stock Fundamental Analysis

NASDAQ:SRRK - Nasdaq - US80706P1030 - Common Stock - Currency: USD

35.99  +0.44 (+1.24%)

After market: 36.1748 +0.18 (+0.51%)

Fundamental Rating

2

Taking everything into account, SRRK scores 2 out of 10 in our fundamental rating. SRRK was compared to 555 industry peers in the Biotechnology industry. While SRRK seems to be doing ok healthwise, there are quite some concerns on its profitability. SRRK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SRRK had negative earnings in the past year.
In the past year SRRK has reported a negative cash flow from operations.
In the past 5 years SRRK always reported negative net income.
In the past 5 years SRRK always reported negative operating cash flow.
SRRK Yearly Net Income VS EBIT VS OCF VS FCFSRRK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -64.82%, SRRK is doing worse than 61.98% of the companies in the same industry.
The Return On Equity of SRRK (-84.58%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -64.82%
ROE -84.58%
ROIC N/A
ROA(3y)-47.57%
ROA(5y)-41.66%
ROE(3y)-64.04%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
SRRK Yearly ROA, ROE, ROICSRRK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SRRK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRRK Yearly Profit, Operating, Gross MarginsSRRK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for SRRK has been increased compared to 1 year ago.
The number of shares outstanding for SRRK has been increased compared to 5 years ago.
Compared to 1 year ago, SRRK has an improved debt to assets ratio.
SRRK Yearly Shares OutstandingSRRK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRRK Yearly Total Debt VS Total AssetsSRRK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

SRRK has an Altman-Z score of 16.94. This indicates that SRRK is financially healthy and has little risk of bankruptcy at the moment.
SRRK's Altman-Z score of 16.94 is amongst the best of the industry. SRRK outperforms 92.25% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that SRRK is not too dependend on debt financing.
The Debt to Equity ratio of SRRK (0.16) is worse than 68.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 16.94
ROIC/WACCN/A
WACCN/A
SRRK Yearly LT Debt VS Equity VS FCFSRRK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

SRRK has a Current Ratio of 10.25. This indicates that SRRK is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 10.25, SRRK is doing good in the industry, outperforming 79.28% of the companies in the same industry.
SRRK has a Quick Ratio of 10.25. This indicates that SRRK is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 10.25, SRRK is doing good in the industry, outperforming 79.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.25
Quick Ratio 10.25
SRRK Yearly Current Assets VS Current LiabilitesSRRK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

SRRK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.53%.
EPS 1Y (TTM)-21.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SRRK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.26%
EPS Next 2Y12.8%
EPS Next 3Y27.5%
EPS Next 5Y23.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRRK Yearly Revenue VS EstimatesSRRK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2019 2020 2021 2022 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SRRK Yearly EPS VS EstimatesSRRK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SRRK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRRK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRRK Price Earnings VS Forward Price EarningsSRRK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRRK Per share dataSRRK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as SRRK's earnings are expected to grow with 27.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.8%
EPS Next 3Y27.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRRK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCHOLAR ROCK HOLDING CORP

NASDAQ:SRRK (7/3/2025, 8:10:39 PM)

After market: 36.1748 +0.18 (+0.51%)

35.99

+0.44 (+1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners118.28%
Inst Owner Change12.42%
Ins Owners3.75%
Ins Owner Change10.87%
Market Cap3.42B
Analysts85.33
Price Target51.44 (42.93%)
Short Float %16.54%
Short Ratio11.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.69%
Min EPS beat(2)0.64%
Max EPS beat(2)0.74%
EPS beat(4)3
Avg EPS beat(4)-0.75%
Min EPS beat(4)-7.78%
Max EPS beat(4)3.39%
EPS beat(8)5
Avg EPS beat(8)0.01%
EPS beat(12)8
Avg EPS beat(12)4.94%
EPS beat(16)10
Avg EPS beat(16)7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.74%
EPS NQ rev (3m)-0.62%
EPS NY rev (1m)-4%
EPS NY rev (3m)-7.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-10.61%
Revenue NY rev (3m)-8.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.94
P/tB 10.94
EV/EBITDA N/A
EPS(TTM)-2.54
EYN/A
EPS(NY)-1.79
Fwd EYN/A
FCF(TTM)-2.42
FCFYN/A
OCF(TTM)-2.42
OCFYN/A
SpS0
BVpS3.29
TBVpS3.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.82%
ROE -84.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.57%
ROA(5y)-41.66%
ROE(3y)-64.04%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.25
Quick Ratio 10.25
Altman-Z 16.94
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.34%
Cap/Depr(5y)103.43%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.56%
EPS Next Y-4.26%
EPS Next 2Y12.8%
EPS Next 3Y27.5%
EPS Next 5Y23.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.24%
EBIT Next 3Y34.81%
EBIT Next 5YN/A
FCF growth 1Y-72.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.59%
OCF growth 3YN/A
OCF growth 5YN/A